GLENMARK
Invest Now
Start SIP in
GLENMARK
Performance
- Low
- ₹1,359
- High
- ₹1,397
- 52 Week Low
- ₹985
- 52 Week High
- ₹1,831
- Open Price₹1,381
- Previous Close₹1,381
- Volume743,468
Investment Returns
- Over 1 Month -9.27%
- Over 3 Month -4.31%
- Over 6 Month -18.65%
- Over 1 Year + 29.66%
Smart Investing Starts Here Start SIP with Glenmark Pharmaceuticals for Steady Growth!
Glenmark Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- -220.7
- PEG Ratio
- -2.8
- Market Cap Cr
- 38,803
- P/B Ratio
- 4.6
- Average True Range
- 49.74
- EPS
- 0
- Dividend Yield
- 0.2
- MACD Signal
- -13.7
- RSI
- 44.25
- MFI
- 54.81
Glenmark Pharmaceuticals Financials
Glenmark Pharmaceuticals Technicals
EMA & SMA
Current Price
₹1,375.00
-6.2
(-0.45%)

-
- Bearish Moving Average 16
-
- Bullish Moving Average 0
- 20 Day
- ₹1,404.11
- 50 Day
- ₹1,425.67
- 100 Day
- ₹1,452.59
- 200 Day
- ₹1,423.66
Resistance and Support
1377.07
- R3 1,433.33
- R2 1,415.27
- R1 1,395.13
- S1 1,356.93
- S2 1,338.87
- S3 1,318.73
Glenmark Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends
Date | Purpose | Remarks |
---|---|---|
2025-02-14 | Quarterly Results | |
2024-11-14 | Quarterly Results | |
2024-08-14 | Quarterly Results | |
2024-05-24 | Audited Results & Final Dividend | |
2024-02-14 | Quarterly Results |
Glenmark Pharmaceuticals F&O
About Glenmark Pharmaceuticals
- NSE Symbol
- GLENMARK
- BSE Symbol
- 532296
- Chairman & Managing Director
- Mr. Glenn Saldanha
- ISIN
- INE935A01035
Similar Stocks to Glenmark Pharmaceuticals
Glenmark Pharmaceuticals FAQs
Glenmark Pharmaceuticals share price is ₹1,375 As on 03 May, 2025 | 16:28
The Market Cap of Glenmark Pharmaceuticals is ₹38802.6 Cr As on 03 May, 2025 | 16:28
The P/E ratio of Glenmark Pharmaceuticals is -220.7 As on 03 May, 2025 | 16:28
The PB ratio of Glenmark Pharmaceuticals is 4.6 As on 03 May, 2025 | 16:28
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.